Beta Drugs (NSE:BETA) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
90 GF Score
Price ₹2,055.20
GF Value ₹2,044.94
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Beta Drugs Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Beta Drugs  (NSE:BETA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Beta Drugs Cyclically Adjusted PS Ratio Related Terms


Beta Drugs Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Cyclically Adjusted PS Ratio Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.74 4.21 6.65 8.80 4.63

Beta Drugs Semi-Annual Data
Sep17 Mar18 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.65 8.39 8.80 8.16 4.63

NSE:BETA vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beta Drugs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Cyclically Adjusted PS Ratio falls into.


NSE:BETA
90GF Score
Beta Drugs Ltd NSE:BETA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Beta Drugs's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar26 is calculated as:

For example, Beta Drugs's adjusted Revenue per Share data for the fiscal year that ended in Mar26 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar26 (Change)*Current CPI (Mar26)
=379.256/164.2724*164.2724
=379.256

Current CPI (Mar26) = 164.2724.

Beta Drugs Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 386.093 105.196 602.917
201803 55.282 109.786 82.718
201903 72.311 118.202 100.495
202003 89.620 124.705 118.055
202103 114.174 131.771 142.336
202203 181.795 138.822 215.124
202303 224.715 146.865 251.350
202403 292.675 153.035 314.167
202503 348.930 157.552 363.814
202603 379.256 164.272 379.256

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,055.20 is trading 0.5% above its estimated GF Value™ of ₹2,044.94. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹2,044.94 vs. price of ₹2,055.20 (0.5% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score

Get the complete analysis for NSE:BETA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,055.20
Price
₹2,044.94
GF Value